ASCO 2016

Local consolidative therapy (LCT) to improve progression-free survival (PFS) in patients with oligometastatic non-small cell lung cancer (NSCLC) who receive induction systemic therapy (IST): Results of a multi-institutional phase II randomized study

Conference Correspondent - ASCO 2016

Retrospective and preclinical studies have provided evidence for a “limited metastatic” phenotype in non–small-cell lung cancer (NSCLC), and the role of aggressive local therapy in this subset of patients is controversial and has not been explored in randomized clinical studies. [ Read More ]

IFCT-1001 CHIVA trial: A phase II study of carboplatin (Ca) plus pemetrexed (P) followed by P maintenance, as first-line therapy for human immunodeficiency virus (HIV)-associated advanced non-squamous non-small-cell lung cancer (NS-NSCLC)

Conference Correspondent - ASCO 2016

Lung cancer and especially nonsquamous non–small-cell lung cancer (NS-NSCLC) is the first cause of mortality by cancer in the HIV population, and the prognosis of lung cancer is worse in HIV-positive individuals.1 However, recommendations for treatment of advanced NSCLC are [ Read More ]

Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN solid tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression

Conference Correspondent - ASCO 2016

Avelumab is a fully human anti–PD-L1 immunoglobulin G1 antibody that binds PD-L1 and inhibits PD-1/PD-L1 interactions, but leaves the PD-1/PD-L2 pathway intact. This agent is under clinical investigation in multiple cancers.1 Verschraegen and colleagues reported on the safety and clinical [ Read More ]

An open-label phase 2 trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928)

Conference Correspondent - ASCO 2016

BRAF V600E mutations occur in 1% to 2% of lung adenocarcinomas and act as an oncogenic driver.1 The BRAF inhibitor dabrafenib has demonstrated clinical activity (33% overall response rate [ORR], with a median progression-free survival [PFS] of 5.5 months as [ Read More ]